Clinical Study

Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients

Table 2

Management of BKV infection prior to addition of ciprofloxacin.

ā€‰Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Patient 9

Time from transplant to BKV diagnosis (days)9192113224691023195140
SCr at diagnosis (mg/dL)0.541.971.271.641.21.582.121.031.08
Viremia at diagnosis (copies/mL)9032 * 106785004530031900362004940010700500
Viruria at diagnosis (copies/mL)4600 * 1064100 * 1063000 * 1061200 * 1061700 * 106>500 * 106116 * 106170 * 1065 * 106
Immunosuppression management prior to ciprofloxacinMMF reduction,
Tac to CsA
MMF stoppedMMF stopped,
CsA reduction
MMF reduction,
Tac reduction
MMF stopped,
Tac to CsA
MMF stoppedMMF stoppedMMF reduction,
Tac reduction
MMF stopped
Cidofovir prior to ciprofloxacinNoYesYesYesYesYesYesYesYes
Leflunomide prior to ciprofloxacinNoNoNoNoYesNoNoNoYes
IVIG prior to ciprofloxacinNoNoYesNoYesNoNoYesYes
Time from BKV diagnosis to ciprofloxacin (days)59771302171751999165379

Abbreviations: BKV: BK polyomavirus; SCr: serum creatinine; IVIG: intravenous immunoglobulin; BKVAN: BK virus associated nephropathy; MMF: mycophenolate mofetil; Tac: tacrolimus; CsA: cyclosporine A.